Vaxart Inc - Asset Resilience Ratio
Vaxart Inc (VXRT) has an Asset Resilience Ratio of 5.71% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Vaxart Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Vaxart Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Vaxart Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Vaxart Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VXRT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.28 Million | 5.71% |
| Total Liquid Assets | $10.28 Million | 5.71% |
Asset Resilience Insights
- Limited Liquidity: Vaxart Inc maintains only 5.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vaxart Inc Industry Peers by Asset Resilience Ratio
Compare Vaxart Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Vaxart Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Vaxart Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.37% | $9.99 Million | $186.08 Million | -10.55pp |
| 2024-12-31 | 15.92% | $26.49 Million | $166.39 Million | +10.52pp |
| 2023-12-31 | 5.40% | $4.96 Million | $91.83 Million | -26.91pp |
| 2022-12-31 | 32.31% | $49.70 Million | $153.85 Million | +22.02pp |
| 2021-12-31 | 10.28% | $22.74 Million | $221.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $152.58 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $35.23 Million | -- |
| 2017-12-31 | 52.12% | $20.90 Million | $40.10 Million | +25.57pp |
| 2016-12-31 | 26.55% | $19.30 Million | $72.70 Million | +10.30pp |
| 2015-12-31 | 16.25% | $12.90 Million | $79.40 Million | +4.93pp |
| 2014-12-31 | 11.32% | $12.90 Million | $114.00 Million | +9.19pp |
| 2011-12-31 | 2.12% | $2.08 Million | $97.97 Million | -45.83pp |
| 2010-12-31 | 47.95% | $54.60 Million | $113.87 Million | +2.65pp |
| 2009-12-31 | 45.30% | $59.49 Million | $131.32 Million | +28.73pp |
| 2008-12-31 | 16.57% | $23.90 Million | $144.22 Million | +15.90pp |
| 2007-12-31 | 0.67% | $1.60 Million | $238.57 Million | -11.55pp |
| 2006-12-31 | 12.22% | $32.50 Million | $265.88 Million | +10.65pp |
| 2005-12-31 | 1.57% | $5.17 Million | $329.34 Million | -0.70pp |
| 2004-12-31 | 2.27% | $8.35 Million | $368.17 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more